Abstract 2170
Background
Little is known about the associations between treatment outcome for immune checkpoint inhibitors and metastatic sites in patients with advanced non-small cell lung cancer (NSCLC). Furthermore, these previous studies included patients irrespective of their PD-L1 status and treatment lines. Therefore, we conducted a multicentered retrospective study to investigate the predictive factors of metastatic sites as first-line pembrolizumab efficacy in patients with PD-L1 tumor proportion score (TPS) ≥50% advanced NSCLC.
Methods
We retrospectively analyzed patients with advanced NSCLC and PD-L1 TPS ≥ 50% who received pembrolizumab as the first-line therapy at 11 institutions between February 2017 and April 2018. Clinical data including metastatic sites at the time of administering pembrolizumab treatment were collected. Treatment outcome of pembrolizumab was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Results
In total, 213 patients were included in the study. The median age was 71 years (range 39-91). Of the 213 patients, 176 (83%) were men, 172 (81%) had Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1. The major metastatic sites were thoracic lymph nodes metastasis (77%), intrapulmonary metastasis (31%), bone metastasis (28%), and malignant pleural effusion (26%). In multivariate analysis, poor PS (hazard ratio: 1.82, 95.0% confidence interval: 1.15–2.30; P = 0.046) and malignant pleural effusion (hazard ratio: 1.52, 95.0% confidence interval: 1.01–2.30; P = 0.046) was identified as an independent predictor of shorter progression free survival in patients treated with pembrolizumab.
Conclusions
In patients with advanced NSCLC and PD-L1 TPS ≥50% who received first-line pembrolizumab, poor PS and malignant pleural effusion are independent predictors of pembrolizumab efficacy.
Clinical trial identification
UMIN000032470.
Editorial acknowledgement
Legal entity responsible for the study
Hanshin Oncology clinical Problem Evaluation group (HOPE).
Funding
Has not received any funding.
Disclosure
H. Kawachi: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. M. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. A. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. K. Hirano: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Yokoyama: Honoraria (self): Taiho Pharmaceutical Co., Ltd. T. Ishida: Honoraria (self): Merck Sharp & Dohme, Corp. D. Fujimoto: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Hirashima: Honoraria (self): Taiho Pharmaceutical Co., Ltd. M. Kanazu: Honoraria (self): Merck Sharp & Dohme, Corp. T. Kumagai: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. All other authors have declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract